INOVIO to Present at Key Scientific Conferences on DNA Medicines
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy INO?
Source: PRnewswire
- Conference Participation: INOVIO will present its research on gene transfer in hemophilia A mice at the American Society of Gene and Cell Therapy Annual Meeting on May 12, 2026, showcasing the correction of bleeding phenotype through in vivo Factor VIII gene transfer by electroporation in skeletal muscle cells, which is expected to enhance its recognition in the gene therapy field.
- Clinical Research Presentation: At the American Society of Clinical Oncology Annual Meeting on May 30, INOVIO will present findings on B cell responses in patients with Recurrent Respiratory Papillomatosis treated with its DNA immunotherapy INO-3107, potentially providing new data to support clinical applications of its products.
- Technological Innovation: INOVIO focuses on developing and commercializing DNA medicines aimed at treating and protecting against HPV-related diseases, cancer, and infectious diseases, with its technology optimizing the design and delivery of innovative DNA medicines, which may lead new trends in the biotechnology sector.
- Information Sharing: INOVIO has announced that available abstracts will be shared on its website following the conferences, further enhancing its transparency and influence in the scientific community, which is expected to attract more attention from investors and researchers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.370
Low
3.00
Averages
7.33
High
13.00
Current: 1.370
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
INOVIO to Present at Key Scientific Conferences on DNA Medicines
- Conference Participation: INOVIO will present its research on gene transfer in hemophilia A mice at the American Society of Gene and Cell Therapy Annual Meeting on May 12, 2026, showcasing the correction of bleeding phenotype through in vivo Factor VIII gene transfer by electroporation in skeletal muscle cells, which is expected to enhance its recognition in the gene therapy field.
- Clinical Research Presentation: At the American Society of Clinical Oncology Annual Meeting on May 30, INOVIO will present findings on B cell responses in patients with Recurrent Respiratory Papillomatosis treated with its DNA immunotherapy INO-3107, potentially providing new data to support clinical applications of its products.
- Technological Innovation: INOVIO focuses on developing and commercializing DNA medicines aimed at treating and protecting against HPV-related diseases, cancer, and infectious diseases, with its technology optimizing the design and delivery of innovative DNA medicines, which may lead new trends in the biotechnology sector.
- Information Sharing: INOVIO has announced that available abstracts will be shared on its website following the conferences, further enhancing its transparency and influence in the scientific community, which is expected to attract more attention from investors and researchers.
See More
Trump Promises Full Report on Hantavirus Outbreak
- Outbreak Overview: The hantavirus outbreak aboard the Dutch-flagged cruise ship Hondius has resulted in three deaths and six confirmed infections among 150 passengers, prompting global attention, with Trump promising a detailed report on Friday, indicating the government's seriousness about the situation.
- Vaccine Development Update: Moderna's partnership with Korea University to develop an mRNA hantavirus vaccine has gained attention, receiving a $176 million government award in 2024, highlighting its critical role in pandemic response and potential to accelerate vaccine development timelines.
- Market Reaction: Vaccine manufacturers and biodefense companies saw stock rallies on Friday night, with Emergent BioSolutions up 3%, Inovio and Novavax each gaining 2%, and Moderna rising 1%, reflecting investor optimism regarding vaccine development amid the outbreak.
- Investor Sentiment: On Stocktwits, retail sentiment for Inovio and Novavax was extremely bullish, while Moderna showed positive sentiment, indicating high market interest in hantavirus-related companies, with Moderna's stock surging 102% over the past year.
See More
INOVIO to Release Q1 2026 Financial Results on May 13
- Earnings Release Schedule: INOVIO will announce its Q1 2026 financial results after market close on May 13, providing crucial insights into the company's financial health and operational performance, which will aid investors in assessing market positioning.
- Conference Call Details: Following the earnings release, INOVIO will host a conference call and webcast at 4:30 p.m. ET, where financial results will be discussed and a business update provided, enhancing engagement with investors.
- Webcast Availability: The live webcast will be archived for 90 days, ensuring that investors who cannot attend in real-time can access key information, thereby improving transparency and communication between the company and its stakeholders.
- Company Overview: INOVIO focuses on developing and commercializing DNA medicines aimed at treating and preventing HPV-related diseases, cancer, and infectious diseases, showcasing its innovative capabilities and market potential in the biotechnology sector.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the overstated prospects of the INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, highlighting its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the class action.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Inovio in the Eastern District of Pennsylvania on behalf of investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, with a deadline of April 7, 2026, for investors to apply as lead plaintiffs, indicating the urgency of legal action.
- Allegations of False Statements: The lawsuit alleges that Inovio made false and misleading statements during the class period, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which could hinder the timely submission of the INO-3107 Biologics License Application (BLA), thereby impacting investor confidence in the company's prospects.
- FDA Review Findings: On December 29, 2025, the FDA accepted Inovio's INO-3107 BLA but noted that the company did not provide adequate information to justify eligibility for accelerated approval, leading to a significant overestimation of the regulatory and commercial prospects by investors.
- Stock Price Plunge Impact: Following the FDA announcement, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share, reflecting a pessimistic market sentiment regarding the company's future, which may further erode investor confidence.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Inovio Pharmaceuticals and certain officers, alleging violations of federal securities laws from October 10, 2023, to December 26, 2025, seeking damages for affected investors.
- False Statements Allegations: The complaint claims that throughout the class period, defendants made materially false and misleading statements regarding the CELLECTRA device's manufacturing deficiencies and the regulatory prospects of INO-3107, leading to investor misjudgment about the company's future.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by April 7, 2026, to participate in potential recovery, with the assurance that they do not need to serve as lead plaintiffs to share in any recovery.
- Law Firm Background: Bronstein, Gewirtz & Grossman LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors, emphasizing its role in restoring market integrity and accountability.
See More
INOVIO to Present at Key Scientific Conferences on DNA Medicines
- Conference Participation: INOVIO will present its research on gene transfer in hemophilia A mice at the American Society of Gene and Cell Therapy Annual Meeting on May 12, 2026, showcasing the correction of bleeding phenotype through in vivo Factor VIII gene transfer by electroporation in skeletal muscle cells, which is expected to enhance its recognition in the gene therapy field.
- Clinical Research Presentation: At the American Society of Clinical Oncology Annual Meeting on May 30, INOVIO will present findings on B cell responses in patients with Recurrent Respiratory Papillomatosis treated with its DNA immunotherapy INO-3107, potentially providing new data to support clinical applications of its products.
- Technological Innovation: INOVIO focuses on developing and commercializing DNA medicines aimed at treating and protecting against HPV-related diseases, cancer, and infectious diseases, with its technology optimizing the design and delivery of innovative DNA medicines, which may lead new trends in the biotechnology sector.
- Information Sharing: INOVIO has announced that available abstracts will be shared on its website following the conferences, further enhancing its transparency and influence in the scientific community, which is expected to attract more attention from investors and researchers.
See More
Trump Promises Full Report on Hantavirus Outbreak
- Outbreak Overview: The hantavirus outbreak aboard the Dutch-flagged cruise ship Hondius has resulted in three deaths and six confirmed infections among 150 passengers, prompting global attention, with Trump promising a detailed report on Friday, indicating the government's seriousness about the situation.
- Vaccine Development Update: Moderna's partnership with Korea University to develop an mRNA hantavirus vaccine has gained attention, receiving a $176 million government award in 2024, highlighting its critical role in pandemic response and potential to accelerate vaccine development timelines.
- Market Reaction: Vaccine manufacturers and biodefense companies saw stock rallies on Friday night, with Emergent BioSolutions up 3%, Inovio and Novavax each gaining 2%, and Moderna rising 1%, reflecting investor optimism regarding vaccine development amid the outbreak.
- Investor Sentiment: On Stocktwits, retail sentiment for Inovio and Novavax was extremely bullish, while Moderna showed positive sentiment, indicating high market interest in hantavirus-related companies, with Moderna's stock surging 102% over the past year.
See More
INOVIO to Release Q1 2026 Financial Results on May 13
- Earnings Release Schedule: INOVIO will announce its Q1 2026 financial results after market close on May 13, providing crucial insights into the company's financial health and operational performance, which will aid investors in assessing market positioning.
- Conference Call Details: Following the earnings release, INOVIO will host a conference call and webcast at 4:30 p.m. ET, where financial results will be discussed and a business update provided, enhancing engagement with investors.
- Webcast Availability: The live webcast will be archived for 90 days, ensuring that investors who cannot attend in real-time can access key information, thereby improving transparency and communication between the company and its stakeholders.
- Company Overview: INOVIO focuses on developing and commercializing DNA medicines aimed at treating and preventing HPV-related diseases, cancer, and infectious diseases, showcasing its innovative capabilities and market potential in the biotechnology sector.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the overstated prospects of the INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, highlighting its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the class action.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Inovio in the Eastern District of Pennsylvania on behalf of investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, with a deadline of April 7, 2026, for investors to apply as lead plaintiffs, indicating the urgency of legal action.
- Allegations of False Statements: The lawsuit alleges that Inovio made false and misleading statements during the class period, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which could hinder the timely submission of the INO-3107 Biologics License Application (BLA), thereby impacting investor confidence in the company's prospects.
- FDA Review Findings: On December 29, 2025, the FDA accepted Inovio's INO-3107 BLA but noted that the company did not provide adequate information to justify eligibility for accelerated approval, leading to a significant overestimation of the regulatory and commercial prospects by investors.
- Stock Price Plunge Impact: Following the FDA announcement, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share, reflecting a pessimistic market sentiment regarding the company's future, which may further erode investor confidence.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Inovio Pharmaceuticals and certain officers, alleging violations of federal securities laws from October 10, 2023, to December 26, 2025, seeking damages for affected investors.
- False Statements Allegations: The complaint claims that throughout the class period, defendants made materially false and misleading statements regarding the CELLECTRA device's manufacturing deficiencies and the regulatory prospects of INO-3107, leading to investor misjudgment about the company's future.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by April 7, 2026, to participate in potential recovery, with the assurance that they do not need to serve as lead plaintiffs to share in any recovery.
- Law Firm Background: Bronstein, Gewirtz & Grossman LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors, emphasizing its role in restoring market integrity and accountability.
See More
